About: A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice
Creator	Cox, Manon Petric, Martin Chubet, Rick Holtz, Katherine Post, Penny Zhou, Zhimin Mcpherson, Clifton
Source	Elsevier; Medline; PMC
abstract	Abstract A recombinant SARS-CoV spike (S) glycoprotein vaccine produced in insect cells in a pre-clinical development stage is described. A truncated version of S glycoprotein, containing only the ecto-domain, as well as a His-tagged full-length version were cloned and expressed in a serum-free insect cell line, ExpresSF+®. The proteins, purified to apparent homogeneity by liquid column chromatography, were formulated without adjuvant at 3, 9, 27, and 50μg per dose in phosphate saline and used to immunize mice. Both antigens in each formulation elicited a strong immune response after two or three vaccinations with the antigen. Neutralizing antibody titers correlated closely with standard ELISA reactivity against the S glycoprotein. The truncated S protein was also formulated with an adjuvant, aluminum hydroxide, at 1μg per dose (±adjuvant), and 5μg per dose (±adjuvant). Significantly enhanced immune responses, manifested by higher titers of serum ELISA and viral neutralizing antibodies, were achieved in adjuvanted groups with fewer doses and lower concentration of S glycoprotein. These findings indicate that the ecto-domain of SARS-CoV S glycoprotein vaccine, with or without adjuvant, is immunogenic and induces high titers of virus neutralizing antibodies to levels similar to those achieved with the full S glycoprotein vaccine.
has issue date	2006-04-24(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2006.01.059
bibo:pmid	16497416
has license	els-covid
sha1sum (hex)	96e9bf5d58a1ba692047da7ffc07a3e1fb86c4da
schema:url	https://doi.org/10.1016/j.vaccine.2006.01.059
resource representing a document's title	A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice
has PubMed Central identifier	PMC7115485
has PubMed identifier	16497416
schema:publication	Vaccine
resource representing a document's body	covid:96e9bf5d58a1ba692047da7ffc07a3e1fb86c4da#body_text
is schema:about of	named entity 'GLYCOPROTEIN' named entity 'MANIFESTED BY' named entity 'PROTEIN ' named entity 'STAGE IS' covid:arg/96e9bf5d58a1ba692047da7ffc07a3e1fb86c4da named entity 'NEUTRALIZING ANTIBODIES' named entity 'RECOMBINANT' named entity 'CLINICAL DEVELOPMENT' named entity 'ALUMINUM HYDROXIDE' named entity 'SERUM' named entity 'DOSE' named entity 'VERSION' named entity 'GLYCOPROTEIN' named entity 'LEVELS' named entity 'SALINE' named entity 'CONCENTRATION OF' named entity 'STANDARD' named entity 'SPIKE' named entity 'ELICITS' named entity 'RECOMBINANT' named entity 'IMMUNE RESPONSE' named entity 'EXPRESSED' named entity 'DOSES' named entity 'VACCINE' named entity 'TAGGED' named entity 'BACULOVIRUS' named entity 'SARS-ASSOCIATED CORONAVIRUS' named entity 'MICE' named entity 'HIGH' named entity 'SIMILAR' named entity 'ANTIGEN' named entity 'ANTIBODY TITERS' named entity 'FINDINGS' named entity 'DEVELOPMENT STAGE' named entity 'APPARENT' named entity 'PHOSPHATE' named entity 'LIQUID COLUMN CHROMATOGRAPHY' named entity 'HIGHER' named entity 'DOMAIN' named entity 'DESCRIBED' named entity 'CLONED' named entity 'HIGH' named entity 'FREE' named entity 'TRUNCATED' named entity 'STRONG' named entity 'SARS-COV' named entity 'IMMUNOGENIC' named entity '28S' named entity 'INSECT CELL' named entity 'PROTEINS' named entity 'PRE-CLINICAL' named entity 'VACCINATIONS' named entity 'CORRELATED' named entity 'FORMULATION' named entity 'NEUTRALIZING ANTIBODIES' named entity 'ELISA' named entity 'VIRUS' named entity 'LOWER' named entity 'CELL LINE' named entity 'ADJUVANT' named entity 'ELICITED' named entity 'REACTIVITY' named entity 'PURIFIED' named entity 'MICE' named entity 'S PROTEIN' named entity 'HOMOGENEITY' named entity 'ECTO' named entity 'INSECT' named entity 'LENGTH' named entity 'ANTIGENS' named entity 'USED' named entity 'CONTAINING' named entity 'ENHANCED' named entity 'THESE' named entity 'NEUTRALIZING ANTIBODY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software